Skip to main content

Table 3 Susceptibility percentage and median zone diameter (mm) of Staphylococcus aureus isolates against sulfonamide derivatives and some antimicrobials determined by disc diffusion method.

From: Antimicrobial activity of some sulfonamide derivatives on clinical isolates of Staphylococus aureus

Antimicrobials

Inhibition zone diameter

(mm)a

Zone diameter (mm)

Tested S. aureus clinical isolates

Susceptibility range (%) (n = 50)b

Name

Concentration (μg)

R

I

S

Range

Median

R

I

Sc

Oxacillin

1 μg

≤10

11–12

≥13

0–23

11.5

30(60)

0

20(40)

Trimetoprim (SXT)

25 μg

≤10

11–15

≥16

21.5–32.5

27

0

0

50(100)

Compound I

500 μg

≤12

13–16

≥17

12–28

20

1(2)

7(14)

42(84)

Compound II

500 μg

≤12

13–16

≥17

11–25

18

3(6)

22(44)

25(50)

Compound III

500 μg

≤12

13–16

≥17

11–19

15

13(26)

19(38)

18(36)

Compound IV

500 μg

≤12

13–16

≥17

0–11

5.5

50(100)

0

0

  1. aZone of inhibition diameter (mm) by disc diffusion method susceptibility testing interpretavive guidelines based on NCCLS 2003.
  2. bNumber of parentheses indicate the total number of clinical S. aureus isolates tested.
  3. cS = susceptible; I = intermediate; R = resistant
  4. dTrimetoprim-sulphamethoxazole (SXT) is being taken as a positive control for approximate comparision compounds data